These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 15857354

  • 1. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR.
    Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB.
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [Abstract] [Full Text] [Related]

  • 4. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin inhibition in heart failure.
    McMurray JJ.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S17-22. PubMed ID: 15526237
    [Abstract] [Full Text] [Related]

  • 6. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 7. Valsartan in chronic heart failure.
    Ripley TL.
    Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
    [Abstract] [Full Text] [Related]

  • 8. [ACE inhibitors and/or sartans in heart failure: is there a difference?].
    Vachiéry JL.
    Rev Med Brux; 2003 Sep; 24(4):A249-52. PubMed ID: 14606288
    [Abstract] [Full Text] [Related]

  • 9. Exploring new treatment strategies in heart failure.
    Swedberg K.
    Blood Press Suppl; 2000 Sep; 1():44-8. PubMed ID: 11059637
    [Abstract] [Full Text] [Related]

  • 10. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.
    Circulation; 2004 Oct 26; 110(17):2618-26. PubMed ID: 15492298
    [Abstract] [Full Text] [Related]

  • 11. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 12. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    McKelvie RS.
    J Hypertens Suppl; 2006 Mar 21; 24(1):S9-13. PubMed ID: 16601580
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin receptor blockers in heart failure.
    Stergren J, McMurray JJ.
    J Renin Angiotensin Aldosterone Syst; 2003 Sep 21; 4(3):171-5. PubMed ID: 14608522
    [Abstract] [Full Text] [Related]

  • 14. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H, Komuro I.
    Nihon Rinsho; 2004 May 21; 62(5):995-1002. PubMed ID: 15148833
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec 21; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 16. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 17. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
    Hennekens CH, Kowalczykowski M, Hollar D.
    J Cardiovasc Pharmacol Ther; 2006 Jun 20; 11(2):149-52. PubMed ID: 16891293
    [Abstract] [Full Text] [Related]

  • 18. Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT.
    Voors AA, van Veldhuisen DJ.
    Int J Cardiol; 2004 Dec 20; 97(3):345-8. PubMed ID: 15561317
    [Abstract] [Full Text] [Related]

  • 19. Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
    Cohn JN.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 20; 1(2 Suppl):S38-40. PubMed ID: 17199220
    [Abstract] [Full Text] [Related]

  • 20. Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Komajda M.
    Heart Fail Monit; 2002 Jun 20; 2(3):85-7. PubMed ID: 12634889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.